About Us
Portfolio
Arthur Pharma
Portfolio
Praxgen has over 40 products under development at various stages that have been and will be filed with the FDA and Chinese FDA.
About Us
Arthur Pharma
Portfolio
Praxgen Pharmaceuticals, formerly SunGen Pharma, was founded in 2016 by a team of distinguished pharma executives. The name Praxgen reflects our commitment to a practical and accessible path to patient health through high-quality generic pharmaceuticals.
Arthur Pharma
Arthur Pharma
Company Introduction
Arthur Pharmaceutical Co., Ltd.,isfounded in March, 2020. An established pharmaceutical company focusing on complex generic drug development and production. Our newly established injection facility comply with FDA cGMP and China GMP requirements. Currently, more than 30 products are under development.
Arthur Group LLC, our subsidiary company, is located in New Jersey, with its main business on regulatory filing and US Market distribution.
Stage I : Arthur Pharma covers an area of 5600m² for its R&D center, which include four teams, the API department, OSD formulation department, Injection formulation department, and R&D department. OurR&D team are located in Jiaxing,Zhejiang,China.
Stage II: Arthur Pharma is currently establishing an injectablefacility with an area of 33,000 m². It is planned for the production of different injection products, including the oncology products, pre-fill syringe products, and ordinary injection products. Our oral solid productmanufacturinglines are on designing stage.
Company Introduction
Company Introduction
Company Introduction
Praxgenis a specialty pharmaceutical company (subsidiary of Arthur Groups) focused on the development, manufacturing and marketing of high-quality generic prescription pharmaceuticals that improve patient health while creating stakeholder value. We specialize in difficult-to-manufacture and complex dosage forms, including ophthalmics, injectables, topicals and oral solids.
We have Research and Development facilities in Princeton, NJ and Monmouth Junction, NJ, and several manufacturing facilities across North America and Asia through partnerships and contract manufacturing.
Joint Product Development
Praxgenis seeking partners for joint product development for U.S. and international markets.
ANDA, 505(b)(2) & NDA
Dr. Isaac Liu
Company Introduction
Dr. Zhang Wei CSO
PhD in Biophysics and Biochemistry, Stanford University Founder and CEO of Shangjin Pharmaceutical
Pfizer Pharmaceuticals
Senior Vice President, Global Strategic Planning and M&A President, Global Contract Machining, Asia Pacific
Ingredient Department Asia Pacific President
President, Novartis Pharmaceuticals (Asia Pacific)
Senior Business Management consultant of McKinsey
Dr. Zhang Wei CSO
Company Introduction
Dr. Zhang Wei CSO
Nearly 30 years of experience in R&D analysis, quality assurance and quality control
Zhejiang University Bachelor, Master New York University Ph.D., Postdoctoral Fellow
Senior Director of Analysis, SUNGENPharmaceuticals, USA
Director of Analysis, Teva Pharmaceutical Industries Ltd. Israel
Barr Laboratories Ltd Analytical Director
Beijing Institute of Technology (China) Associate Professor
Dr. Yang Shicheng CTO
Dr. Gopi Inti Vice President, Scientific Operations USA and Asia Sites
Dr. Gopi Inti Vice President, Scientific Operations USA and Asia Sites
More than 30 years experience in solid dosage development
Ph.D., China Pharmaceutical University
Postdoctoral fellow at Purdue University
Senior Director of Pharmaceutical R&D, Shionogi Pharmaceuticals, Japan
Senior Director of Product Development and Technology Transfer,
Salus Corporation, USA
Pfizer (China) R&D Manager
Medical Advanced Research
Senior Formulation Researcher,
KV Pharmaceuticals, USA
Dr. Gopi Inti Vice President, Scientific Operations USA and Asia Sites
Dr. Gopi Inti Vice President, Scientific Operations USA and Asia Sites
Dr. Gopi Inti Vice President, Scientific Operations USA and Asia Sites
Dr. Gopi has over 22 years of pharmaceutical research experience with regulatory expertise, having worked with top tier firms including Dr.Reddy's, Mylan CIPLA, InvaGen & Ascent.
He has an extensive background in current FDA regulations and is skilled in cGMP regulated environments.
At Praxgen, He is a part of the executive leadership, plays an integral role in optimizing the R&D portfolio/pipeline strategy and supporting the commercial sales team and general management of
USA and Asia sites.
In the News
SunGen Pharma Rebrands as Praxgen Pharmaceuticals
Oakrum Pharma and SunGen Pharma Announce U.S. Launch of Generic Medrol® (Methylprednisolone)
Oakrum Pharma and SunGen Pharma Announce U.S. Launch of Generic Medrol® (Methylprednisolone)
We are excited to announce that SunGen Pharma has rebranded as Praxgen Pharmaceuticals!
Over the past five years, SunGen focused on actively building a company that can both develop a wide range of drug products while maintaining flexibility and dedication to R&D fundamentals. SunGen is not and has never been affiliated with SUN PHARMA® and/or Sun Pharmaceutical Industries, Ltd.
Our new name, Praxgen Pharmaceuticals, reflects our commitment to patient health. The path to health should be practical and accessible to everyone, and we aim to help achieve that through high-quality generic pharmaceuticals.
Amidst this thrilling name change, Praxgen’s quality remains constant. We will continue to focus on developing exemplary prescription drugs for introduction into the market to bring accessibility to the masses.
Oakrum Pharma and SunGen Pharma Announce U.S. Launch of Generic Medrol® (Methylprednisolone)
Oakrum Pharma and SunGen Pharma Announce U.S. Launch of Generic Medrol® (Methylprednisolone)
Oakrum Pharma and SunGen Pharma Announce U.S. Launch of Generic Medrol® (Methylprednisolone)
Oakrum and SunGen announced the U.S. launch and commercial shipment of a generic version of Medrol® (Methylprednisolone) in 4 mg tablets. It is anticipated that the product will serve the retail market with annual sales in the U.S. exceeding $110 million in the aggregate for the 12-month period ending December 31, 2018 according to available data from IQVIA.
SunGen Pharma Receives Seventh ANDA Approval from US FDA
Oakrum Pharma and SunGen Pharma Announce U.S. Launch of Generic Medrol® (Methylprednisolone)
SunGen Pharma Receives Seventh ANDA Approval from US FDA
The seventh approved ANDA is for Fosaprepitant for Injection 150mg/vial. This drug product is used for treatment of cyclic vomiting syndrome and late-stage, chemotherapy-induced vomiting. This is a sub-blockbuster product of over $350M US market size for 2018 according to IQVIA. Emend®’s patent expired on Sep 4th and SunGen obtained its ANDA approval on Sep 5th, which includes it in the first wave of all generic approvals for Emend®.